SOHO State of the Art Updates and Next Questions: Chronic Myeloid Leukemia and Pregnancy: "Per Aspera Ad Astra"
Clin Lymphoma Myeloma Leuk. 2023 Dec 12:S2152-2650(23)02189-4. doi: 10.1016/j.clml.2023.11.011. Online ahead of print.ABSTRACTChronic myeloid leukemia (CML) has evolved from an invariably fatal disease to a chronic disorder that can be treated with targeted drugs and allows survival expectations approaching age-matched controls. Thus, pregnancy and conception in CML should not be precluded anymore; however, to ensure the well-being of both the mother and the developing fetus careful planning and management are required. Tyrosine Kinase Inhibitors (TKIs) are not genotoxic or carcinogenic but can pose a risk to the developin...
Source: Clinical Lymphoma and Myeloma - December 27, 2023 Category: Cancer & Oncology Authors: Elisabetta Abruzzese Malgorzata Monika Trawinska Paolo De Fabritiis Simona Bernardi Source Type: research
The Impact of Time From Diagnosis to Initiation of Chemotherapy on Survival of Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma in the Veterans Health Administration
CONCLUSION: Our study shows that a TDT equal to or less than 1 week is associated with adverse clinical factors, worse outcomes, and response in DLBCL, even after adjusting for multiple known poor prognostic factors. This was the first time that response to first-line therapy was correlated to time to treatment. Our findings support ongoing efforts to improve currently standardized prognostic tools and the incorporation of TDT into clinical trials to avoid selection bias.PMID:38151390 | DOI:10.1016/j.clml.2023.11.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 27, 2023 Category: Cancer & Oncology Authors: Gabriel Roman Souza Zohra Nooruddin Sophia Lee Lauren Boyle Kana Tai Lucero Snegha Ananth Kathleen Franklin Michael Mader Esteban Toro Velez Amna Naqvi Supreet Kaur Source Type: research
Multiparametric Flow Cytometry in the Evaluation of Plasma Cell Proliferative Disorders: Current Paradigms for Clinical Practice
Clin Lymphoma Myeloma Leuk. 2023 Nov 27:S2152-2650(23)02184-5. doi: 10.1016/j.clml.2023.11.006. Online ahead of print.ABSTRACTDiagnosis of plasma cell proliferative disorders (PCPDs) is primarily based on the demonstration of monoclonal protein (M-Protein) in blood and/ or urine which often precedes clinical manifestations of the disease. The basic pathophysiology behind the M-protein presence is the proliferation of clonal plasma cells (PCs) in bone marrow or extramedullary sites and is assessed using cytomorphology and immunophenotyping. The role of multiparametric flow cytometry (MFC) for PC identification is technicall...
Source: Clinical Lymphoma and Myeloma - December 23, 2023 Category: Cancer & Oncology Authors: Ritu Gupta Dragan Jevremovic Smith J Mathew Shaji Kumar Source Type: research
Multiparametric Flow Cytometry in the Evaluation of Plasma Cell Proliferative Disorders: Current Paradigms for Clinical Practice
Clin Lymphoma Myeloma Leuk. 2023 Nov 27:S2152-2650(23)02184-5. doi: 10.1016/j.clml.2023.11.006. Online ahead of print.ABSTRACTDiagnosis of plasma cell proliferative disorders (PCPDs) is primarily based on the demonstration of monoclonal protein (M-Protein) in blood and/ or urine which often precedes clinical manifestations of the disease. The basic pathophysiology behind the M-protein presence is the proliferation of clonal plasma cells (PCs) in bone marrow or extramedullary sites and is assessed using cytomorphology and immunophenotyping. The role of multiparametric flow cytometry (MFC) for PC identification is technicall...
Source: Clinical Lymphoma and Myeloma - December 23, 2023 Category: Cancer & Oncology Authors: Ritu Gupta Dragan Jevremovic Smith J Mathew Shaji Kumar Source Type: research
Multiparametric Flow Cytometry in the Evaluation of Plasma Cell Proliferative Disorders: Current Paradigms for Clinical Practice
Clin Lymphoma Myeloma Leuk. 2023 Nov 27:S2152-2650(23)02184-5. doi: 10.1016/j.clml.2023.11.006. Online ahead of print.ABSTRACTDiagnosis of plasma cell proliferative disorders (PCPDs) is primarily based on the demonstration of monoclonal protein (M-Protein) in blood and/ or urine which often precedes clinical manifestations of the disease. The basic pathophysiology behind the M-protein presence is the proliferation of clonal plasma cells (PCs) in bone marrow or extramedullary sites and is assessed using cytomorphology and immunophenotyping. The role of multiparametric flow cytometry (MFC) for PC identification is technicall...
Source: Clinical Lymphoma and Myeloma - December 23, 2023 Category: Cancer & Oncology Authors: Ritu Gupta Dragan Jevremovic Smith J Mathew Shaji Kumar Source Type: research
Multiparametric Flow Cytometry in the Evaluation of Plasma Cell Proliferative Disorders: Current Paradigms for Clinical Practice
Clin Lymphoma Myeloma Leuk. 2023 Nov 27:S2152-2650(23)02184-5. doi: 10.1016/j.clml.2023.11.006. Online ahead of print.ABSTRACTDiagnosis of plasma cell proliferative disorders (PCPDs) is primarily based on the demonstration of monoclonal protein (M-Protein) in blood and/ or urine which often precedes clinical manifestations of the disease. The basic pathophysiology behind the M-protein presence is the proliferation of clonal plasma cells (PCs) in bone marrow or extramedullary sites and is assessed using cytomorphology and immunophenotyping. The role of multiparametric flow cytometry (MFC) for PC identification is technicall...
Source: Clinical Lymphoma and Myeloma - December 23, 2023 Category: Cancer & Oncology Authors: Ritu Gupta Dragan Jevremovic Smith J Mathew Shaji Kumar Source Type: research
Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia
CONCLUSIONS: Patients with CML-CP treated with 1L dasatinib achieved higher rates of, with shorter times to, MMR and DMR versus 1L imatinib. These clinically meaningful improvements were observed across subgroups.PMID:38135632 | DOI:10.1016/j.clml.2023.10.005 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 22, 2023 Category: Cancer & Oncology Authors: Andrew J Klink Scott J Keating John Brokars Bruce Feinberg Elias Jabbour Source Type: research
SOHO State of the Art Update and Next Questions: Novel Therapies for Polycythemia Vera
Clin Lymphoma Myeloma Leuk. 2023 Nov 27:S2152-2650(23)02182-1. doi: 10.1016/j.clml.2023.11.004. Online ahead of print.ABSTRACTIn the recent years, landmark advancements in the treatment of polycythemia vera (PV) have been achieved. We witnessed the regulatory approval of ropeginterferon and the advanced clinical development of other novel agents that may affect the underlying pathophysiological mechanisms of the disease. Agents with the potential of disease modification may soon overtake preceding treatment options that were based on the patient's age and history of thrombosis. Recent studies using ropeginterferon in low-r...
Source: Clinical Lymphoma and Myeloma - December 22, 2023 Category: Cancer & Oncology Authors: Lucia Masarova Helen T Chifotides Source Type: research
Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma
In conclusion, the duration of the PFS significantly influences survival, regardless of HR cytogenetic features. Therefore, it should be considered an important parameter for risk stratification in patients experiencing a relapse.PMID:38135634 | DOI:10.1016/j.clml.2023.11.008 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 22, 2023 Category: Cancer & Oncology Authors: Sarah Goldman-Mazur Alissa Visram S Vincent Rajkumar Prashant Kapoor Angela Dispenzieri Martha Q Lacy Morie A Gertz Francis K Buadi Suzanne R Hayman David Dingli Taxiarchis Kourelis Wilson Gonsalves Rahma Warsame Eli Muchtar Nelson Leung Robert A Kyle Sha Source Type: research
Folinic Acid Over: Rescue of Intermediate Dose Methotrexate
Clin Lymphoma Myeloma Leuk. 2023 Dec 5:S2152-2650(23)02190-0. doi: 10.1016/j.clml.2023.12.003. Online ahead of print.NO ABSTRACTPMID:38135635 | DOI:10.1016/j.clml.2023.12.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 22, 2023 Category: Cancer & Oncology Authors: Ian J Cohen Source Type: research
SOHO State of the Art Updates and Next Questions: Oral Therapy in Acute Myeloid Leukemia
Clin Lymphoma Myeloma Leuk. 2023 Dec 1:S2152-2650(23)02187-0. doi: 10.1016/j.clml.2023.11.009. Online ahead of print.ABSTRACTWith the recent development of several new effective agents, treatment of patients with acute myeloid leukemia (AML) is evolving. Molecularly targeted agents developed against leukemogenic pathways are demonstrating significant promise both as monotherapy and in combination with standard regimens. Although oral chemotherapeutic agents have long been used in the treatment of various malignancies, their use in patients with AML has been hitherto limited. The availability of most newly approved targeted...
Source: Clinical Lymphoma and Myeloma - December 19, 2023 Category: Cancer & Oncology Authors: Patrice Nasnas Farhad Ravandi Source Type: research
SOHO State of the Art Updates and Next Questions: Oral Therapy in Acute Myeloid Leukemia
Clin Lymphoma Myeloma Leuk. 2023 Dec 1:S2152-2650(23)02187-0. doi: 10.1016/j.clml.2023.11.009. Online ahead of print.ABSTRACTWith the recent development of several new effective agents, treatment of patients with acute myeloid leukemia (AML) is evolving. Molecularly targeted agents developed against leukemogenic pathways are demonstrating significant promise both as monotherapy and in combination with standard regimens. Although oral chemotherapeutic agents have long been used in the treatment of various malignancies, their use in patients with AML has been hitherto limited. The availability of most newly approved targeted...
Source: Clinical Lymphoma and Myeloma - December 19, 2023 Category: Cancer & Oncology Authors: Patrice Nasnas Farhad Ravandi Source Type: research
SOHO State of the Art Updates and Next Questions: Oral Therapy in Acute Myeloid Leukemia
Clin Lymphoma Myeloma Leuk. 2023 Dec 1:S2152-2650(23)02187-0. doi: 10.1016/j.clml.2023.11.009. Online ahead of print.ABSTRACTWith the recent development of several new effective agents, treatment of patients with acute myeloid leukemia (AML) is evolving. Molecularly targeted agents developed against leukemogenic pathways are demonstrating significant promise both as monotherapy and in combination with standard regimens. Although oral chemotherapeutic agents have long been used in the treatment of various malignancies, their use in patients with AML has been hitherto limited. The availability of most newly approved targeted...
Source: Clinical Lymphoma and Myeloma - December 19, 2023 Category: Cancer & Oncology Authors: Patrice Nasnas Farhad Ravandi Source Type: research
SOHO State of the Art Updates and Next Questions: Oral Therapy in Acute Myeloid Leukemia
Clin Lymphoma Myeloma Leuk. 2023 Dec 1:S2152-2650(23)02187-0. doi: 10.1016/j.clml.2023.11.009. Online ahead of print.ABSTRACTWith the recent development of several new effective agents, treatment of patients with acute myeloid leukemia (AML) is evolving. Molecularly targeted agents developed against leukemogenic pathways are demonstrating significant promise both as monotherapy and in combination with standard regimens. Although oral chemotherapeutic agents have long been used in the treatment of various malignancies, their use in patients with AML has been hitherto limited. The availability of most newly approved targeted...
Source: Clinical Lymphoma and Myeloma - December 19, 2023 Category: Cancer & Oncology Authors: Patrice Nasnas Farhad Ravandi Source Type: research
Approach to Older Adults With Philadelphia-Chromosome Negative Acute Lymphoblastic Leukemia
Clin Lymphoma Myeloma Leuk. 2023 Nov 23:S2152-2650(23)02159-6. doi: 10.1016/j.clml.2023.10.011. Online ahead of print.ABSTRACTPhiladelphia-chromosome-negative (Ph-neg) acute lymphoblastic leukemia (ALL) has historically been associated with poor outcomes in older patients due to adverse disease biology, as well as inferior tolerance of conventional chemotherapy. Fortunately, novel therapies, including inotuzumab ozogamicin, blinatumomab, and venetoclax, are now being incorporated into first-line therapy to improve efficacy and decrease toxicity of initial therapy. Inotuzumab ozogamicin, alone or in combination with low int...
Source: Clinical Lymphoma and Myeloma - December 15, 2023 Category: Cancer & Oncology Authors: Shai Shimony Marlise R Luskin Source Type: research
